Active Ingredient History
Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membranebound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells. Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner. The mechanism of blood glucose lowering also involves a delay in gastric emptying. GLP-1(7-37) has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once daily administration, is a result of self-association that delays absorption, plasma protein binding and stability against metabolic degradation by DPP-IV and NEP. Liraglutide, a subcutaneous, once-daily GLP-1 agonist, is approved for the treatment of type 2 diabetes in the United States and Europe. It also has been studied for weight loss. Liraglutide helps to induce and sustain weight loss in patients with obesity. Its efficacy is comparable to other available agents but it offers the unique benefit of improved glycemic control. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acromegaly (Phase 4)
Alzheimer Disease (Phase 2)
Anastomosis, Surgical (Phase 2)
Angina Pectoris (Phase 2)
Angina, Stable (Phase 2)
Arthritis, Psoriatic (Phase 2)
Atrial Fibrillation (Phase 4)
Autonomic Nervous System Diseases (Phase 2)
Bariatric Surgery (Phase 4)
Bile Acids and Salts (Phase 4)
Binge-Eating Disorder (Phase 3)
Bipolar Disorder (Phase 3)
Blood Glucose (Phase 3)
Blood Pressure (Phase 4)
Body Fat Distribution (Phase 4)
Body Weight (Phase 2)
Brain Death (Phase 3)
Brain Diseases (Phase 4)
Cardiovascular Diseases (Phase 4)
Coronary Artery Bypass (Phase 2)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 2)
COVID-19 (Early Phase 1)
Depressive Disorder, Major (Phase 3)
Diabetes Complications (Phase 4)
Diabetes, Gestational (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetic Nephropathies (Phase 4)
Eating (Phase 4)
Endometrial Hyperplasia (Phase 2/Phase 3)
Fatty Liver (Phase 4)
Fertilization in Vitro (Phase 2/Phase 3)
Gastrectomy (Phase 2)
Gastrointestinal Diseases (Phase 1)
General Surgery (Phase 4)
Geriatrics (Phase 3)
Glucose Intolerance (Phase 3)
Growth and Development (Phase 2)
Growth Hormone (Phase 4)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 2)
Heart Failure (Phase 2)
Heart Failure, Diastolic (Phase 4)
HIV Infections (Phase 4)
Hunger (Phase 4)
Hyperglycemia (Phase 4)
Hypertension (Phase 4)
Hypoglycemia (Phase 4)
Hypogonadism (Phase 4)
Infertility, Female (Phase 4)
Inflammation (Phase 4)
Insulin Resistance (Phase 4)
Insulin Secretion (Phase 4)
Ischemic Attack, Transient (Phase 3)
Ischemic Stroke (Phase 3)
Kidney Failure, Chronic (Phase 4)
Leukemia, Myeloid, Acute (Early Phase 1)
Liraglutide (Phase 4)
Magnetic Resonance Imaging (Phase 4)
Masked Hypertension (Phase 4)
Mental Disorders (Phase 4)
Metabolic Diseases (Phase 4)
Metabolic Syndrome (Phase 4)
Metabolism (Phase 3)
Metformin (Phase 4)
Microbiota (Phase 4)
Microvascular Angina (Phase 4)
Multiple Sclerosis (Early Phase 1)
Myocardial Infarction (Phase 2)
Myocardium (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Obesity, Abdominal (Phase 4)
Obesity, Morbid (Phase 4)
Opiate Substitution Treatment (Phase 1/Phase 2)
Opioid-Related Disorders (Phase 1/Phase 2)
Osteoarthritis (Phase 4)
Osteoarthritis, Knee (Phase 4)
Osteoporosis (Phase 4)
Overweight (Phase 4)
Paraproteinemias (Phase 4)
Parkinson Disease (Phase 2)
Pediatric Obesity (Phase 3)
Peripheral Arterial Disease (Phase 4)
Pituitary ACTH Hypersecretion (Phase 4)
Polycystic Ovary Syndrome (Phase 4)
Post-Acute COVID-19 Syndrome (Early Phase 1)
Pouchitis (Phase 2)
Prader-Willi Syndrome (Phase 4)
Prediabetic State (Phase 4)
Psoriasis (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Renal Dialysis (Phase 2)
Reperfusion Injury (Phase 2)
Short Bowel Syndrome (Phase 2)
Sleep Apnea Syndromes (Phase 1/Phase 2)
Sleep Disorders, Intrinsic (Phase 3)
Smoking Cessation (Phase 2)
Stomach Diseases (Phase 4)
Sweat Gland Diseases (Phase 2)
Therapeutic Equivalency (Phase 1)
Vascular Diseases (Phase 4)
Weight Loss (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
